Indegene Share Price

Healthcare Services company Indegene announced Q4FY26 & FY26 results Q4FY26 Quarterly Consolidated Financial Highlights: Revenue from Operations: Rs 10,034 million in Q4FY26, compared to Rs 7,556 million in Q4FY25, representing a YoY increase of 32.8%. On a QoQ basis, revenue grew by 6.5% from Rs 9,421 million in Q3FY26. Total Income: Rs 10,142 million in Q4FY26, up from Rs 7,812 million in Q4FY25 (29.8% YoY) and up from Rs 9,615 million in Q3FY26 (5.5% QoQ). Profit Before Tax (PBT): Rs 1,051 million in Q4FY26, a decrease of 29.6% YoY from Rs 1,493 million and a decrease of 22.0% QoQ from Rs 1,347 million. (Note: This includes an exceptional loss of Rs 203 million). Profit for the Period (PAT): Rs 797 million in Q4FY26, down 32.2% YoY from Rs 1,176 million and down 22.5% QoQ from Rs 1,029 million. Earnings Per Share (EPS): Basic EPS stood at Rs 3.32 and Diluted EPS at Rs 3.30 for Q4FY26. FY26 Quarterly Consolidated Financial Highlights: Revenue from Operations: Rs 35,105 million for FY26, compared to Rs 28,393 million in FY25, representing a YoY growth of 23.6%. Total Income: Rs 35,825 million for FY26, up from Rs 29,465 million in FY25 (21.6% YoY). Profit Before Tax (PBT): Rs 5,250 million in FY26, a slight decrease of 2.7% YoY from Rs 5,393 million in FY25. Profit for the Year (PAT): Rs 4,011 million in FY26, compared to Rs 4,067 million in FY25. Dividend: The Board recommended a final dividend of Rs 2.25 per equity share for FY26. Q4FY26 Quarterly Standalone Financial Highlights: Revenue from Operations: Rs 3,682 million in Q4FY26, compared to Rs 2,667 million in Q4FY25 (38.1% YoY) and Rs 2,901 million in Q3FY26 (26.9% QoQ). Profit for the Period (PAT): Rs 721 million in Q4FY26, up 33.0% YoY from Rs 542 million and up 107.2% QoQ from Rs 348 million. FY26 Quarterly Standalone Financial Highlights: Revenue from Operations: Rs 12,206 million for FY26, compared to Rs 10,936 million in FY25 (11.6% YoY). Profit for the Year (PAT): Rs 2,119 million in FY26, compared to Rs 1,813 million in FY25 (16.9% YoY). Business Highlights Enterprise Commercial Solutions: Reported revenue of Rs 24,605 million in FY26, up from Rs 19,348 million in FY25. The segment result was Rs 4,492 million. Enterprise Medical Solutions: Reported revenue of Rs 9,298 million in FY26, up from Rs 8,025 million in FY25. The segment result was Rs 2,435 million. Others: Reported revenue of Rs 1,202 million in FY26. Inorganic Growth and Acquisitions BioPharm Parent Holdings Inc.: Acquired 100% interest on October 1, 2025, for an aggregate purchase consideration of Rs 8,821 million (USD 99.77 million). Warn & Co Limited: Acquired 100% interest on October 16, 2025, for a consideration of Rs 464 million. Cake Kommunikations Holdings GmbH: Entered into an agreement on November 10, 2025, to acquire the Cake Group for an aggregate consideration of Rs 904 million. Sahamati Foundation: Subsequent to the year-end, on April 10, 2026, the company invested Rs 10.00 million to acquire a 2.00% equity stake. Manish Gupta, Chairman & CEO, Indegene, said: “FY26 was a landmark year for Indegene. We surpassed Rs 1,000 crore in quarterly revenue for the first time, and Rs 3,500 crore for the full year.” “This reflects growing strategic depth in our largest client relationships, with 53 clients contributing over USD 1 million in annual revenue, alongside breakthrough GenAI-led wins across Commercial and Medical. With a strong pipeline and an industry-leading revenue per employee of USD 75k, we will build on this momentum in FY27.” Suhas Prabhu, CFO, Indegene, said: “FY26 reflected disciplined financial execution. Our cash conversion ratio of 162% reflects continued strong underlying cash generation, while higher non-cash charges impact the reported profits.” “Reflecting this strength, the Board has recommended a final dividend of Rs 2.25 per share - a 12.5% increase over FY25. With healthy margins, strong cash generation, and recent acquisitions now integrated, we enter FY27 with confidence.” Result PDF

• Trendlyne
• 1 month 2 weeks ago

Conference Call with Indegene Ltd. Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 1 month 2 weeks ago

Healthcare Services company Indegene announced Q3FY26 results Revenue: Rs 9,421 million against Rs 7,204 million during Q3FY25, change 31%. EBITDA: Rs 1,747 million against Rs 1511 million during Q3FY25, change 16%. EBITDA Margin: 18.5% for Q3FY26. PAT: Rs 1,026 million against Rs 1097 million during Q3FY25, change -6%. PAT Margin: 10.9% for Q3FY26. Manish Gupta, Chairman & CEO, Indegene, said: “We delivered a standout Q3FY26, with revenue growing over 30% YoY and 17% sequentially, marking it the first USD 100 million+ revenue quarter. Our revenue per employee has crossed the USD 70K annual mark - the highest in the industry - underscoring the tangible impact of technology and AI in scaling productivity.”, “This quarter, 3 customers surpassed the USD 25 million annual revenue milestone, and 52 customers exceeded the USD 1 million annual level, reinforcing the depth of our client relationships. We also secured several breakthrough wins, where clients are partnering with us to combine our proven execution strength with AI to transform their operations and unlock differentiated, measurable outcomes. This momentum positions Indegene well to continue delivering sustained, profitable growth over the long term.” Suhas Prabhu, CFO, Indegene, said: “During the quarter, we completed the acquisitions of BioPharm, a US-focused life sciences omnichannel business, and Warn & Co., a UK-based consulting firm - both strategically important additions that deepen our domain expertise and expand our high-value capabilities. Our cash and investments are a healthy Rs 13,954 million, net of acquisition outflows, with continued cash generation strengthening our balance sheet. EBITDA adjusted for one-time expenses, rose to Rs 1,747 million, growing 15.7% YoY and 19.6% sequentially.” “While reported PAT remained flat at Rs 1,026 million this quarter, due to one-time expenses and higher non-cash amortization, these impacts are transient. As integration synergies are realized, acquisition-related costs taper off, and growth momentum continues, we expect profitability to continue to strengthen, supporting further EPS expansion.” Result PDF

• Trendlyne
• 4 months 2 weeks ago